The UK National Institute for Health and Care Excellence (NICE) has recommended Teva Pharmaceutical Industries’ Cinqaero (reslizumab) for the treatment of patients with severe eosinophilic asthma.

Cinqaero is a humanised interleukin-5 (IL-5) antagonist monoclonal antibody.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

IL-5 is the most selective eosinophil-active cytokine and causes maturation, activation and survival of eosinophils.

Cinqaero binds to human IL-5 and prevents it from binding to the IL-5 receptor, which helps reduce eosinophilic inflammation.

Having been recommended in NICE’s Final Appraisal Determination (FAD), the treatment can be used as an add-on therapy in adult patients with severe eosinophilic asthma that is inadequately controlled despite high-dose inhaled corticosteroids, in addition to another medicinal product for maintenance treatment.

See Also:

"The future of respiratory care shows great promise, and we are proud to be at the forefront of providing innovative medications for such a patient population whose quality of life is often severely impacted by asthma."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Teva Pharmaceutical Industries Global Respiratory Medicines senior vice-president and head Sven Dethlefs said: “Teva is very pleased to receive this decision by NICE as we seek to expand the availability of reslizumab (Cinqaero) globally in an effort to ensure that patients living with severe, uncontrolled asthma have access to this treatment option.

“The future of respiratory care shows great promise, and we are proud to be at the forefront of providing innovative medications for such a patient population whose quality of life is often severely impacted by asthma.”

The recommendation is based on a dossier submitted to NICE for a Single Technology Appraisal (STA).

In August last year, The European Commission (EC) granted marketing authorisation for Cinqaero.